# Akouos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/akouos

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.akouos.com
- Total disclosed funding: $138M
- Latest round: Series B (Feb 27, 2020)
- Investors on record: 16

## About

Akouos, Inc. is a biotechnology company specializing in precision genetic therapies aimed at restoring and preserving high-acuity hearing in individuals with disabling hearing loss.Founded in 2016 in Boston, US, Akouos, Inc. develops gene therapies to address hearing loss. The company, co-founded by Manny Simons and others, has secured funding through rounds including a TRADE SALE, raising a total of USD 487.00 mn. Their most recent deal occurred on June 25, 2020, involving an acquisition by Eli Lilly and Company for approximately USD 610 mn. The firm has completed 5 deals to date.Akouos focuses on developing precision genetic therapies to restore, improve, and preserve hearing for individuals with disabling hearing loss. Their products utilize advanced gene therapy technologies to target genetic causes of hearing loss, with an aim to deliver effective clinical treatments for patients. Akouos collaborates with healthcare providers and the DHH community to ensure accessibility of its therapies across the US and other regions.In 2021, Akouos reported an EBITDA of USD -81.40 mn. The company's revenue model is based on partnerships and direct transactions with healthcare providers for gene therapy products, ensuring streamlined access to their offerings to meet healthcare needs. Pricing details are not publicly disclosed, but the revenue generation strategy targets significant unmet needs in hearing health.Following the acquisition by Eli Lilly and Company, Akouos plans to use the funds to advance its lead program, AK-OTOF, into first-in-human clinical studies and establish in-house GMP manufacturing capabilities at its new Boston Seaport office. The company aims to accelerate the development of pipeline programs addressing other forms of sensorineural hearing loss and expand its team in research and clinical development. The recent funding will support these initiatives to enhance the accessibility and efficacy of their therapies.

## Funding rounds

- Series B, Feb 27, 2020, $105M — New Enterprise Associates, Sofinnova Investments, Healthcare Royalty Partners, Novartis Venture Fund, 5AM Ventures, Fidelity Investments, Mass General Brigham Ventures, RA Capital Management, EcoR1 Capital, Cormorant Asset Management, Wu Capital, Pivotal Life Sciences, Surveyor Capital, PagsGroup, Polaris Founders Capital, Cowen Healthcare Investments
- Series A, Aug 6, 2018, $25M — New Enterprise Associates, Sofinnova Investments, Novartis Venture Fund, 5AM Ventures, Mass General Brigham Ventures, RA Capital Management
- Seed, Nov 13, 2017, $7.6M — New Enterprise Associates, 5AM Ventures, Mass General Brigham Ventures

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Seed, Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Seed, Series A, Series B
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Seed, Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- Healthcare Royalty Partners (https://capitalatlas.ai/funds/healthcare-royalty-partners) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Wu Capital — Series B
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B
- Surveyor Capital — Series B
- PagsGroup — Series B
- Polaris Founders Capital (https://capitalatlas.ai/funds/polaris-founders-capital) — Series B
- Cowen Healthcare Investments — Series B